Movalis (Meloxicam)

Meloxicam exerts its effect by selectively inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that drive inflammation, pain and fever. By sparing COX‑1, meloxicam lowers prostaglandin levels at sites of inflammation while preserving protective prostaglandins in the stomach and kidneys, providing anti‑inflammatory and analgesic benefits.

The dose of Movalis is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, renal and hepatic function, and other individual factors. The prescriber will select the appropriate strength, frequency and duration of treatment in accordance with local prescribing guidelines and the product label.

Safety data for meloxicam in pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Movalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Movalis (meloxicam) is a selective COX‑2 inhibitor, which typically offers a lower incidence of gastrointestinal irritation compared with non‑selective NSAIDs such as ibuprofen or diclofenac. However, it shares class‑related risks of cardiovascular events and renal impairment, especially at higher doses or in patients with pre‑existing risk factors.

Movalis injectable solution should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the product. If refrigeration is temporarily unavailable, the product may be kept at controlled room temperature for a limited period as indicated in the product label.

Movalis is supplied as an injectable solution for intramuscular injection. Administration must be performed by a qualified healthcare professional using aseptic technique. The injection site is typically the gluteal or deltoid muscle, and the volume administered follows the prescriber’s instructions based on the selected dose.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as myocardial infarction or stroke, and renal impairment that can lead to acute kidney injury. Patients with a history of peptic ulcer disease, heart disease, or compromised kidney function should be closely monitored, and any signs of severe adverse reactions require immediate medical attention.

Movalis should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and patients with established cardiovascular disease who are at high risk for thrombotic events. It is also contraindicated in patients who have had a recent coronary artery bypass graft (CABG) surgery.